# Community Pharmacy Model

Understand how prescriptions, reimbursement, staffing, and retail sales affect a pharmacy's performance.

- Canonical: https://finamodel.com/templates/pharmacy
- Excel download: https://finamodel.com/templates/pharmacy.xlsx
- Category: Healthcare
- Model type: Operating model
- Difficulty: Intermediate
- Audiences: Investors & analysts, Founders & operators, PE & buy-side, Search-fund and PE buyers, Community pharmacy operators, Healthcare services investors, Lenders, Independent pharmacy operators and owner-pharmacists, Healthcare PE sponsors and roll-up acquirers, Buy-side analysts covering retail health and chain drug, Healthcare investment bankers and transaction advisors
- Tags: pharmacy, community-pharmacy, retail-pharmacy, rollup, dcf, dispensing mix, healthcare services, roll-up, DCF

## Overview

This model helps you assess a community pharmacy or a group of locations. It brings prescription volume, reimbursement, clinical services, and front-of-store sales together with the staffing and operating costs needed to run the business.

Use it to test store growth, prescription demand, pricing, and service mix before making an investment or operating decision. The summary shows the resulting profit, cash flow, and value.

## What's included

- Pharmacy inputs: Year-1 pharmacies, new pharmacies per year, scripts per pharmacy, pharmacists per pharmacy, average script value
- Utilisation: Year-1 utilisation with an annual ramp and a practical ceiling
- Ancillary: clinical encounters per pharmacy and average clinical fee, front-of-store revenue per script and front-of-store gross margin, price escalation
- Cost structure: pharmacist and technician comp and wage with benefits and wage growth, facilities, marketing, technology and SG&A as a percent of gross profit, depreciation, tax
- Capital and working capital: maintenance capex, pharmacy build-out cost per store, NWC, base-year revenue
- Valuation: WACC, terminal growth, net debt, shares outstanding
- Dashboard with pharmacies, scripts, utilisation, revenue per pharmacy and per script, EBITDA margin, EV, per share, and revenue mix
- Pharmacy roll-forward (opening + new = closing) with a capped utilisation ramp driving effective scripts per pharmacy and total scripts
- Four-tier prescription revenue engine (generic, branded, specialty, compounded-and-DME) with per-tier price indices, gross margins, and reimbursement escalation
- Clinical and wellness services revenue (encounters per pharmacy x average clinical fee) and front-of-store OTC retail (scripts x per-script rate)
- P&L with headcount-driven pharmacist and technician labour, gross-profit-geared overhead stack (facilities, marketing, technology, SG&A), EBITDA, depreciation, EBIT, tax, and net income
- Unlevered FCF bridge: NOPAT, depreciation, maintenance capex, de novo build-out capex (new pharmacies x cost per store), and change in NWC discounted at WACC
- DCF valuation: sum of explicit PV plus Gordon-growth terminal value equals enterprise value, less net debt equals equity value and value per share with implied EV/EBITDA
- Dispensing mix: generic, branded, specialty and compounded-and-DME shares, per-tier price indices and gross margins
- Cost structure: pharmacist and technician comp and wage with benefits and wage growth; facilities, marketing, technology and SG&A as % of gross profit; depreciation (% of revenue); tax
- Capital and working capital: maintenance capex %, pharmacy build-out cost per store, NWC % of revenue growth, base-year revenue
- Operations sheet: pharmacy roll-forward, utilisation ramp, scripts per pharmacy, total scripts, staff headcount, scripts per pharmacist
- Revenue sheet: four dispensing tiers, prescription revenue, clinical services, front-of-store and OTC, total revenue
- P&L sheet: revenue to net income with drug and retail cost of goods, labour and overhead, margins, identity check
- FCF sheet: NOPAT, depreciation add-back, capex, change in NWC, unlevered FCF, discount factor, PV
- Valuation sheet: sum of PV, terminal value, enterprise value, equity value, value per share, implied EV/EBITDA
- Pharmacy roll-forward (opening + new = closing) with a utilisation ramp capped at a practical ceiling driving effective scripts per pharmacy and total scripts
- Four-tier prescription revenue engine (generic, branded, specialty, compounded-and-DME) with per-tier price indices, gross margins, and a reimbursement escalation rate
- Clinical and wellness services revenue (encounters per pharmacy x average clinical fee) and front-of-store OTC retail revenue (scripts x per-script rate) with high-contribution clinical margins
- P&L with headcount-driven pharmacist and technician/clerk labour, gross-profit-geared overhead (facilities, marketing, technology, corporate SG&A), EBITDA, depreciation, EBIT, tax, and net income
- DCF valuation: sum of explicit PV plus Gordon-growth terminal value equals enterprise value, less net debt equals equity value and value per share, with implied EV/EBITDA

## Community Pharmacy Financial Model: How This Template Works

This pharmacy financial model template projects the economics of a multi-location community pharmacy group over seven years. It links store growth and prescription demand to dispensing mix, clinical services, and front-of-store sales, then flows through operating costs, cash flow, and a discounted valuation so you can test how reimbursement pressure and service mix affect profit and enterprise value.

### What Drives Pharmacy and Prescription Growth

The model begins with a pharmacy roll-forward: opening stores plus new pharmacies equal closing stores. Each year, the group targets a fixed number of new locations, but a pipeline factor tapers that target as the store count approaches a market-saturation ceiling.

- This reflects the finite number of viable community pharmacy sites. Closing pharmacies then drive the script-volume build, because each store supports a mature number of prescriptions annually.

- A utilisation ramp scales that mature script book from an initial level upward to a practical ceiling, recognising that new or acquired stores take years to build patient relationships. Total scripts, the product of closing pharmacies and effective scripts per pharmacy, is the core volume driver feeding revenue and cost lines.

### How the Dispensing Mix Shapes Revenue and Gross Profit

Prescription revenue is built tier by tier across generic, branded, specialty, and compounded-and-DME categories. Total scripts are split by each tier's share and multiplied by an average script value and a per-tier price index.

- A specialty script carries a price index well above one, while a generic sits far below, so the blended revenue per script emerges directly from the mix. The cost to deliver is the drug cost, calculated as each tier's revenue times one minus that tier's gross margin.

- High-volume generics earn a wide spread, while branded and specialty drugs are largely pass-through. That structural asymmetry means the blended gross margin before PBM fees lands in the mid-twenties, and it is a key lever for understanding profitability.

### The PBM DIR-Fee Clawback and Its Effect on Margins

A defining feature of community pharmacy economics is the pharmacy benefit manager's ability to claw back direct and indirect remuneration fees months after the point of sale. The model prices this explicitly and separately from per-tier dispensing margins.

- The DIR fee starts at a percentage of prescription revenue and escalates linearly each year, and it is netted only against prescription revenue, never against front-of-store or clinical-services revenue. This clawback sits between drug cost of goods and gross profit, so it is additive to the tiered margin structure and can be flexed independently of volume or mix.

- Layering the DIR fee onto dispensing economics is why the blended gross margin settles in the low twenties and why the EBITDA margin compresses modestly across the horizon as the fee escalates faster than the cost-stack ramp.

### Operating Costs, Cash Flow, and Valuation Outputs

Pharmacist and technician labour are headcount-driven and represent the dominant operating cost, loaded for benefits and escalated at a wage-growth rate. Remaining overhead—facilities, marketing, technology, and corporate SG&A—is set as a percentage of gross profit rather than revenue, because most dispensing revenue is pass-through drug cost.

- That structure lets utilisation, front-store attach, and clinical services lift gross profit while labour grows only with headcount and inflation. The cash flow statement then adds depreciation, subtracts maintenance and store build-out capital expenditure, and accounts for working capital tied up in drug inventory and PBM receivables.

- Unlevered free cash flow is discounted at a WACC, and a Gordon-growth terminal value produces enterprise value, equity value, and value per share, alongside a dashboard summarising pharmacies, scripts, revenue, EBITDA, and valuation multiples.

## Dispensing mix drives revenue per script

Revenue is the product of a pharmacy estate, the scripts it fills, and the mix of those scripts. The model makes pharmacy count, scripts per pharmacy, a utilisation ramp, and a four-tier dispensing mix explicit, so total scripts and revenue per script are transparent operating metrics an analyst can flex against the cost stack rather than a top-down growth rate.

## Designed for one-edit responsiveness

Every input, the pharmacy pipeline, scripts per pharmacy, the utilisation ramp, the dispensing mix, the average script value, the full cost stack, capex, working capital, and the WACC, is a named-range cell. Edit one and the operations build, revenue, P&L, free-cash-flow bridge, valuation, and dashboard all recompute. No formula rewrites are needed to test a reimbursement, mix, or expansion scenario.

## An unlevered DCF, not an EBITDA shortcut

A pharmacy group builds out each store and ties up drug inventory and slow-paying PBM receivables, so the model bridges to unlevered free cash flow and discounts it at a WACC with a Gordon-growth terminal value. Enterprise value bridges through net debt to equity value and a per-share figure, and the implied EV/EBITDA falls out as a sanity check against where pharmacy platforms change hands.

## Dispensing-mix economics at the centre

Prescription revenue is built tier by tier: total scripts times each tier share times average script value times a per-tier price index. Because the generic-versus-specialty mix determines both blended revenue per script and blended gross margin, an analyst can flex the mix and watch EBITDA and enterprise value respond immediately.

## Three revenue streams, one integrated model

Thin-margin prescription dispensing, high-contribution clinical and wellness services, and script-driven front-of-store OTC retail are each modelled on their own driver logic and then combined into a single gross profit line. The blend is why the blended gross margin runs in the mid-twenties and EBITDA lands in the high single digits.

## Overhead anchored to gross profit

Facilities, marketing, technology, and corporate SG&A are sized as percentages of gross profit rather than total revenue, because most dispensing revenue is pass-through drug cost. This keeps margin benchmarks consistent with how pharmacy operators and acquirers actually benchmark the cost of running a multi-site platform.

## Workbook structure

### Cover

Workbook overview, sheet legend, units, and tab-colour key.

- Title and scope framing
- Sheet-by-sheet purpose summary
- Units and tab-colour legend

### Assumptions

Every driver in one sheet: pharmacies, utilisation, dispensing mix, costs, capital, valuation.

- Year-1 pharmacies, new pharmacies per year, scripts per pharmacy, pharmacists per pharmacy, average script value
- Utilisation with an annual ramp and a practical ceiling
- Dispensing-tier shares, price indices and gross margins, clinical and front-store inputs, price escalation
- Pharmacist and technician comp and wage, the percent-of-gross-profit overhead lines, depreciation, tax
- Maintenance capex, build-out cost per pharmacy, NWC, base-year revenue
- WACC, terminal growth, net debt, shares

### Operations

Pharmacies, scripts, utilisation, and staff.

- Opening plus new pharmacies equals closing pharmacies
- Utilisation ramps from a Year-1 input, capped at a ceiling
- Scripts per pharmacy equal mature scripts times utilisation
- Total scripts equal closing pharmacies times scripts per pharmacy
- Pharmacist and technician headcount equal closing pharmacies times per-store FTE
- Scripts per pharmacist as a productivity metric

### Revenue

Revenue by dispensing tier and ancillary.

- Each tier equals total scripts times tier share times average script value times price index times escalation
- Prescription revenue subtotal
- Clinical services equal closing pharmacies times clinical encounters times average fee
- Front-of-store and OTC equal total scripts times front-of-store revenue per script
- Total revenue

### P&L

Revenue to net income.

- Revenue from the Revenue sheet
- Drug and retail cost of goods as the inverse of the per-tier margin plus front-store cost
- Gross profit and gross margin
- Pharmacist and technician labour by headcount, the percent-of-gross-profit overhead stack
- EBITDA, depreciation, EBIT, tax on positive EBIT, net income, margins, identity check

### FCF

Unlevered free cash flow bridge.

- EBIT and unlevered tax from the P&L
- NOPAT equals EBIT less unlevered tax
- Add back depreciation
- Maintenance capex on revenue and build-out capex on new pharmacies
- Change in net working capital on revenue growth
- Unlevered free cash flow
- Discount factor and PV of UFCF

### Valuation

Discounted cash flow.

- Sum of PV of explicit UFCF
- Gordon-growth terminal value and its PV
- Enterprise value
- Less net debt to equity value
- Shares outstanding and value per share
- Implied EV/EBITDA

### Dashboard

Headline metrics and revenue mix.

- Pharmacies, scripts, utilisation, revenue per pharmacy and per script
- Revenue and EBITDA
- EBITDA margin
- Enterprise value and value per share
- Revenue mix across prescriptions, clinical services, and front-of-store

### Cover

Workbook overview, sheet legend, tab-colour key, units, and scope framing.

- Title and model scope
- Sheet-by-sheet purpose summary
- Tab-colour legend
- Units and conventions

### Assumptions

Every driver in one place: pharmacy and script economics, utilisation ramp, dispensing tiers, cost structure, capex, working capital, and valuation inputs.

- Y1 pharmacy count, new pharmacies per year, scripts per pharmacy, per-store FTE ratios
- Y1 utilisation rate, annual ramp, and practical ceiling
- Tier shares, per-tier price indices and gross margins, clinical encounter rate and fee, front-of-store rate, reimbursement escalation
- Pharmacist and technician compensation, benefits, wage growth; overhead percentages off gross profit; depreciation, tax; maintenance capex, build-out cost, NWC rate; WACC, terminal growth, net debt, shares

### Operations

Pharmacy roll-forward and script volume build with pharmacist and technician headcount.

- Opening + new = closing pharmacies each year
- Utilisation: Y1 input ramped and capped at practical ceiling
- Effective scripts per pharmacy (scripts per pharmacy x utilisation) and total scripts (closing pharmacies x scripts per pharmacy)
- Pharmacist and technician/clerk FTE counts, total staff, and scripts per pharmacist

### Revenue

Prescription revenue by tier, clinical and wellness services, and front-of-store OTC retail, all escalated at the reimbursement step-up.

- Prescription revenue by tier: total scripts x tier share x average script value x price index x escalation
- Prescription subtotal across four tiers
- Clinical and wellness services: closing pharmacies x encounters per pharmacy x average clinical fee x escalation
- Front-of-store OTC retail: total scripts x per-script rate x escalation; total revenue

### P&L

Revenue through net income with gross-profit-geared overhead and a line-by-line identity check.

- Drug and retail COGS from per-tier margin inverses plus front-of-store retail cost; gross profit and gross margin
- Pharmacist and technician/clerk labour: headcount x wage x wage growth x (1 + benefits)
- Facilities and occupancy, marketing, technology, and corporate SG&A as percentages of gross profit; total opex; EBITDA
- Depreciation, EBIT, tax on positive EBIT, net income, EBITDA and net margins, identity check

### FCF

Unlevered free-cash-flow bridge from NOPAT to PV of UFCF.

- EBIT, unlevered tax, NOPAT; add depreciation
- Less maintenance capex (% of revenue) and de novo build-out capex (new pharmacies x cost per store)
- Revenue growth and change in NWC (inventory and PBM receivable tie-up as fraction of revenue growth)
- Unlevered FCF, discount factor, PV of UFCF

### Valuation

DCF from sum of explicit PVs plus Gordon-growth terminal value to equity value per share.

- Sum of explicit PV of UFCF over the 7-year horizon
- Gordon-growth terminal value and its PV
- Enterprise value less net debt equals equity value; equity value divided by shares equals value per share
- Implied EV/EBITDA

### Dashboard

One-page KPI summary with a seven-year operating table, trend-chart grid, and Revenue to Net Income waterfall.

- KPI card strip: pharmacies, scripts, utilisation, revenue per pharmacy, revenue per script, revenue, EBITDA, EBITDA margin, enterprise value, value per share
- Seven-year operating summary table
- Trend-chart grid across key operating and financial metrics
- Revenue to Net Income waterfall

## Features

- **Dispensing mix drives revenue per script:** Revenue is the product of a pharmacy estate, the scripts it fills, and the mix of those scripts. The model makes pharmacy count, scripts per pharmacy, a utilisation ramp, and a four-tier dispensing mix explicit, so total scripts and revenue per script are transparent operating metrics rather than a top-down growth rate, and the generic-versus-brand-versus-specialty spread is visible in the blend.
- **Labour is the cost, and it is modelled as headcount:** Dispensing is a people-intensive, licence-gated business, so pharmacist and technician/clerk pay is the largest operating line and is built bottom-up from FTEs per pharmacy, wage, benefits and wage inflation. The remaining overhead is geared to gross profit rather than revenue, because the bulk of dispensing revenue is pass-through drug cost, so the EBITDA margin responds the way a real multi-site operator would expect.
- **An unlevered DCF, not an EBITDA shortcut:** A pharmacy group builds out each store and ties up real drug inventory and PBM receivables, so EBITDA overstates cash. The model bridges EBITDA to cash through NOPAT, depreciation, maintenance and build-out capex, and the change in working capital, then discounts the unlevered free-cash-flow stream at a WACC with a Gordon-growth terminal value to a defensible enterprise and equity value.
- **Dispensing-mix economics made explicit:** Prescription revenue is built tier by tier: total scripts times each tier's share times average script value times a per-tier price index. Because generics earn a wide spread on a small dollar ticket and branded or specialty drugs are largely pass-through at a thin margin, the blended revenue per script and the blended gross margin both fall straight out of the mix. Flex the generic-versus-specialty split and watch blended gross margin, EBITDA, and enterprise value all move together.
- **Three-stream revenue architecture:** The model captures all three revenue lines of a community pharmacy: prescription dispensing (the volume-driven core), clinical and wellness services (immunisations, medication therapy management, point-of-care testing) at a near-100% contribution margin, and front-of-store OTC retail at its own gross margin. The blend of thin-margin dispensing lifted by high-margin services is why the blended gross margin runs in the mid-twenties and EBITDA lands in the high single digits.
- **Overhead anchored to gross profit, not revenue:** Facilities and occupancy, marketing, technology, and corporate SG&A are set as percentages of gross profit rather than total revenue. Because the bulk of dispensing revenue is pass-through drug cost, a revenue-based overhead rate would understate the real cost of running a multi-site pharmacy platform relative to the gross profit the business actually earns. This convention keeps margins comparable to how pharmacy operators and PE buyers actually think about the cost structure.

## Use cases

- **Intrinsic valuation:** Set the pharmacy pipeline, utilisation ramp, dispensing mix, the cost stack, and a WACC, and read the enterprise value, equity value, value per share, and implied EV/EBITDA. Sense-check the multiple against where pharmacy platforms change hands.
- **Roll-up and pipeline planning:** Flex new pharmacies per year and the build-out cost per store to see how the de novo and tuck-in pipeline consumes cash and lifts script volume, and watch revenue per pharmacy and the EBITDA margin respond as the group scales.
- **Reimbursement and mix stress test:** Shift the dispensing mix toward generics or specialty, or compress the per-tier margins, to model reimbursement pressure, and read the revenue-per-script, gross-margin, EBITDA-margin and valuation impact.
- **Independent pharmacy roll-up underwriting:** Model a tuck-in acquisition pipeline by flexing the number of new pharmacies per year, the build-out cost per store, and the utilisation ramp on newly opened locations to see how quickly the acquired script book grows into a full contribution margin and what the blended EV/EBITDA implies at acquisition.
- **Reimbursement-pressure scenario analysis:** Shift the per-tier price indices downward to simulate PBM reimbursement cuts or DIR fee drag on branded and specialty scripts. Watch the blended revenue per script, gross margin, and EBITDA margin compress, and identify whether a clinical-services build or a front-store attach can offset the dispensing headwind.
- **Clinical-services expansion case:** Increase clinical encounters per pharmacy and average clinical fee to model the revenue and margin uplift from adding immunisation clinics, medication therapy management, or point-of-care testing. Because clinical services carry a near-100% contribution margin, even a modest encounter volume lifts the blended gross margin and expands EBITDA faster than equivalent prescription volume growth.

## Frequently asked questions

### What is a pharmacy financial model?

A pharmacy financial model captures the seven-year operating economics and intrinsic value of a multi-location community and independent pharmacy group that runs retail dispensing alongside front-of-store retail and clinical services. It rolls a pharmacy count forward, converts a capacity-utilisation ramp into total scripts, prices scripts across a four-tier dispensing mix at a blended average script value and price index, runs the thin-margin drug-cost and labour stack to EBITDA, and discounts an unlevered free-cash-flow stream to enterprise value, equity value, and value per share.

### How is pharmacy revenue built?

Revenue is driven by the pharmacy estate and its utilisation: total scripts equal closing pharmacies times scripts per pharmacy times a utilisation factor that ramps to a ceiling, and prescription revenue splits those scripts across a generic, branded, specialty and compounded-and-DME mix, each priced at a blended average script value times a per-tier price index. Store-driven clinical services and script-driven front-of-store and OTC retail layer on to total revenue.

### Why is the dispensing mix so important?

High-volume generics carry a small price index but a wide gross margin, while branded and specialty drugs carry a large price index but a near-pass-through margin, so both the blended revenue per script and the blended gross margin fall out of the mix. The model makes the per-tier indices and gross margins explicit so an analyst can flex the mix and reimbursement and watch revenue per script, gross profit and EBITDA move together.

### Why an unlevered DCF instead of an EBITDA multiple?

A pharmacy group still builds out each store and ties up drug inventory and slow-paying PBM receivables, so EBITDA overstates cash. The model bridges to unlevered free cash flow, NOPAT plus depreciation, less maintenance and build-out capex, less the change in working capital, and discounts it at a WACC, then adds a Gordon-growth terminal value. The implied EV/EBITDA falls out as a sanity check rather than as the valuation input.

### What is a pharmacy dispensing-mix model?

It is a model that builds prescription revenue tier by tier - total scripts times each tier share (generic, branded, specialty, compounded-and-DME) times a per-tier average script value and price index - so that the blended revenue per script and blended gross margin both fall out of the mix rather than being assumed directly. A shift toward specialty lifts revenue per script but compresses gross margin; a shift toward generics does the opposite.

### How is the utilisation ramp structured?

The model takes a Year 1 utilisation input (the share of mature-capacity scripts a pharmacy actually fills in its first year), adds a fixed number of percentage points per year, and caps it at a practical ceiling. Total scripts equals closing pharmacies times effective scripts per pharmacy (scripts per pharmacy times utilisation), so the ramp is the dominant volume driver in the early years of a de novo or tuck-in pipeline.

### Why is overhead sized off gross profit rather than revenue?

The majority of prescription revenue is pass-through drug cost that the pharmacy collects from a PBM or insurer and remits to the wholesaler. Sizing overhead as a percentage of gross profit reflects the actual cost of running the store and multi-site platform relative to what the business retains after drug cost, and it keeps EBITDA margin benchmarks consistent with how pharmacy operators and acquirers actually report them.

### How does the working-capital charge work in the FCF bridge?

A dispensing business ties up drug inventory held before dispensing and carries PBM and third-party receivables that can settle on a 15-30 day cycle. The model expresses net working capital as a percentage of revenue growth, so as the pharmacy group adds stores or grows script volume the resulting inventory and receivables build-up is captured as a cash outflow in each year.

### What are the headline model outputs?

The model defaults to 25 pharmacies in Year 1 growing to 43 by Year 7, with total scripts rising from approximately 1.72 million to 3.27 million. Revenue grows from approximately $150.9 million to $330.6 million. Blended gross margin runs approximately 26%, EBITDA margin ranges from 8.9% to 9.2%, enterprise value is approximately $139.8 million, equity value per share is approximately $18.15, and the implied EV/EBITDA is approximately 10.5x. All inputs are editable on the Assumptions sheet.

## Related templates

- [Dental Practice](https://finamodel.com/templates/dental-practice)
- [Hospital Operating Model](https://finamodel.com/templates/hospital-model)
- [Franchise Unit Economics Model](https://finamodel.com/templates/franchise-model)
- [Pet Care Roll-Up Model](https://finamodel.com/templates/pet-care)